ArticleFrontiers in oncology2020

Using Co-segregation and Loss of Heterozygosity Analysis to Define the Pathogenicity of Unclassified Variants in Hereditary Breast Cancer Patients.

Rebeca Silveira Grasel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.